Search

Your search keyword '"Roukema, J"' showing total 398 results

Search Constraints

Start Over You searched for: Author "Roukema, J" Remove constraint Author: "Roukema, J"
398 results on '"Roukema, J"'

Search Results

2. P163 Reliability, reproducibility, and responsiveness of home spirometry in regular cystic fibrosis care

3. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. Home monitoring in asthma: towards digital twins

6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

8. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

9. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.

10. Maternal depressive symptoms during pregnancy and infant wheezing up to 2 years of age.

11. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

12. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

15. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

16. FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes

20. Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression

21. Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

22. Gender differences in the use of cardiovascular interventions in HIV?positive persons; the D:A:D Study

25. 665: Forskolin-induced intestinal organoid swelling predicts long-term cystic fibrosis disease progression

26. 563: Real-life initiation of elexacaftor/ivacaftor/tezacaftor in cystic fibrosis patients with severe lung disease

30. Forskolin-induced swelling of intestinal organoids predicts long-term cystic fibrosis disease progression

34. It Is Not Just the FEV1 That Matters, but the Personal Goals We Reach Along the Way: Qualitative, Multicenter, Prospective, Observational Study

38. Forskolin-induced swelling of intestinal organoids predicts long-term cystic fibrosis disease progression

49. eHealth in paediatric asthma. From promise to practice

50. Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Catalog

Books, media, physical & digital resources